HANSOH PHARMAC (Germany) Performance
| 3KY Stock | EUR 2.16 0.06 2.70% |
HANSOH PHARMAC has a performance score of 1 on a scale of 0 to 100. The firm retains a Market Volatility (i.e., Beta) of -0.76, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning HANSOH PHARMAC are expected to decrease at a much lower rate. During the bear market, HANSOH PHARMAC is likely to outperform the market. HANSOH PHARMAC HD at this time retains a risk of 4.54%. Please check out HANSOH PHARMAC sortino ratio, potential upside, and the relationship between the jensen alpha and maximum drawdown , to decide if HANSOH PHARMAC will be following its current trending patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in HANSOH PHARMAC HD 00001 are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable basic indicators, HANSOH PHARMAC is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Price Earnings Ratio | 29.6667 | |
| Dividend Yield | 0.0099 | |
| Payout Ratio | 0.1671 |
HANSOH |
HANSOH PHARMAC Relative Risk vs. Return Landscape
If you would invest 222.00 in HANSOH PHARMAC HD 00001 on September 24, 2024 and sell it today you would lose (6.00) from holding HANSOH PHARMAC HD 00001 or give up 2.7% of portfolio value over 90 days. HANSOH PHARMAC HD 00001 is currently producing 0.0575% returns and takes up 4.5364% volatility of returns over 90 trading days. Put another way, 40% of traded stocks are less volatile than HANSOH, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
HANSOH PHARMAC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HANSOH PHARMAC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as HANSOH PHARMAC HD 00001, and traders can use it to determine the average amount a HANSOH PHARMAC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0127
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | 3KY | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.54 actual daily | 40 60% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average HANSOH PHARMAC is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HANSOH PHARMAC by adding it to a well-diversified portfolio.
HANSOH PHARMAC Fundamentals Growth
HANSOH Stock prices reflect investors' perceptions of the future prospects and financial health of HANSOH PHARMAC, and HANSOH PHARMAC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HANSOH Stock performance.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.063 | |||
| Profit Margin | 0.27 % | |||
| Operating Margin | 0.28 % | |||
| Shares Outstanding | 5.92 B | |||
| Price To Earning | 38.60 X | |||
| Revenue | 9.97 B | |||
| EBITDA | 3.02 B | |||
| Cash And Equivalents | 13.73 B | |||
| Cash Per Share | 2.32 X | |||
| Total Debt | 92.75 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 3.57 X | |||
| Cash Flow From Operations | 2.39 B | |||
| Earnings Per Share | 0.06 X | |||
About HANSOH PHARMAC Performance
By analyzing HANSOH PHARMAC's fundamental ratios, stakeholders can gain valuable insights into HANSOH PHARMAC's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HANSOH PHARMAC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HANSOH PHARMAC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients in the Peoples Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd. HANSOH PHARMAC operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 11645 people.Things to note about HANSOH PHARMAC HD performance evaluation
Checking the ongoing alerts about HANSOH PHARMAC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HANSOH PHARMAC HD help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HANSOH PHARMAC HD had very high historical volatility over the last 90 days | |
| About 82.0% of the company shares are owned by insiders or employees |
- Analyzing HANSOH PHARMAC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HANSOH PHARMAC's stock is overvalued or undervalued compared to its peers.
- Examining HANSOH PHARMAC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HANSOH PHARMAC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of HANSOH PHARMAC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HANSOH PHARMAC's stock. These opinions can provide insight into HANSOH PHARMAC's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HANSOH Stock analysis
When running HANSOH PHARMAC's price analysis, check to measure HANSOH PHARMAC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HANSOH PHARMAC is operating at the current time. Most of HANSOH PHARMAC's value examination focuses on studying past and present price action to predict the probability of HANSOH PHARMAC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HANSOH PHARMAC's price. Additionally, you may evaluate how the addition of HANSOH PHARMAC to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |